Vaishali Pharma (VAISHALI) | Financial Analysis & Statements
Vaishali Pharma Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
311.0M
Gross Profit
4.6M
1.47%
Operating Income
1.3M
0.43%
Net Income
-42.9M
-13.80%
Balance Sheet Metrics
Total Assets
1.1B
Total Liabilities
449.3M
Shareholders Equity
649.2M
Debt to Equity
0.69
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Mar 31, 2025
Annual Income Flow
2025
Vaishali Pharma Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 978.8M | 817.6M | 638.2M | 715.4M | 523.1M |
| Cost of Goods Sold | 856.7M | 744.2M | 546.8M | 635.0M | 461.5M |
| Gross Profit | 122.1M | 73.5M | 91.5M | 80.4M | 61.6M |
| Gross Margin % | 12.5% | 9.0% | 14.3% | 11.2% | 11.8% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 13.9M | 10.3M | 9.1M | 5.0M | 4.7M |
| Other Operating Expenses | 29.8M | 16.6M | 25.2M | 27.5M | 8.1M |
| Total Operating Expenses | 43.8M | 26.9M | 34.3M | 32.5M | 12.8M |
| Operating Income | 59.0M | 63.4M | 89.7M | 64.8M | 40.4M |
| Operating Margin % | 6.0% | 7.8% | 14.1% | 9.1% | 7.7% |
| Non-Operating Items | |||||
| Interest Income | 25.9M | 13.9M | 12.6M | 13.0M | 12.6M |
| Interest Expense | 20.7M | 22.7M | 22.6M | 24.9M | 26.3M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 12.3M | 9.3M | 88.5M | 57.3M | 14.0M |
| Income Tax | 4.1M | 2.1M | 22.4M | 17.0M | 3.6M |
| Effective Tax Rate % | 33.3% | 22.4% | 25.4% | 29.8% | 25.5% |
| Net Income | 8.2M | 7.2M | 66.0M | 40.2M | 10.5M |
| Net Margin % | 0.8% | 0.9% | 10.3% | 5.6% | 2.0% |
| Key Metrics | |||||
| EBITDA | 93.2M | 87.9M | 116.1M | 86.7M | 62.8M |
| EPS (Basic) | - | ₹0.07 | ₹0.63 | ₹0.38 | ₹0.10 |
| EPS (Diluted) | - | ₹0.07 | ₹0.59 | ₹0.38 | ₹0.10 |
| Basic Shares Outstanding | - | 107192130 | 105462130 | 105462130 | 105462130 |
| Diluted Shares Outstanding | - | 107192130 | 105462130 | 105462130 | 105462130 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Vaishali Pharma Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 17.1M | 14.6M | 5.3M | 11.6M | 3.1M |
| Short-term Investments | - | 121.3M | 118.9M | 120.5M | 119.7M |
| Accounts Receivable | 467.2M | 494.3M | 536.1M | 585.1M | 667.3M |
| Inventory | 48.1M | 3.8M | 30.5M | 6.3M | 5.9M |
| Other Current Assets | - | -2.0K | 10.0K | 1.0K | -1 |
| Total Current Assets | 1.0B | 745.2M | 726.7M | 764.3M | 813.0M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 0 | 14.6M | 18.0M | 9.0M | 9.7M |
| Goodwill | 9.2M | 8.0M | 8.6M | 7.7M | 2.9M |
| Intangible Assets | 9.2M | 8.0M | 8.6M | 7.7M | 2.9M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | -1.0K | -2.0K | 1.0K | 1.0K | 1 |
| Total Non-Current Assets | 53.6M | 54.4M | 62.3M | 52.0M | 48.3M |
| Total Assets | 1.1B | 799.6M | 789.0M | 816.2M | 861.3M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 271.4M | 193.9M | 180.0M | 283.8M | 405.4M |
| Short-term Debt | 77.0M | 96.6M | 86.3M | 176.7M | 135.9M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 1.0K | 36.9M | -1.0K | 15.2M | 1 |
| Total Current Liabilities | 400.5M | 330.8M | 320.7M | 519.4M | 592.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 46.2M | 38.3M | 61.1M | 31.4M | 42.6M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | 1.0K | 1.0K | 1.0K | 2 |
| Total Non-Current Liabilities | 48.8M | 40.3M | 63.0M | 33.3M | 44.4M |
| Total Liabilities | 449.3M | 371.2M | 383.7M | 552.7M | 637.1M |
| Equity | |||||
| Common Stock | 260.9M | 107.2M | 105.5M | 105.5M | 105.5M |
| Retained Earnings | 157.3M | 149.1M | 141.9M | 75.9M | 35.7M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 649.2M | 428.4M | 405.3M | 263.5M | 224.2M |
| Key Metrics | |||||
| Total Debt | 123.2M | 134.9M | 147.4M | 208.1M | 178.5M |
| Working Capital | 644.3M | 414.4M | 406.0M | 244.9M | 220.3M |
Balance Sheet Composition
Vaishali Pharma Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 12.3M | 9.3M | 88.5M | 57.3M | 14.0M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -350.8M | 25.4M | 40.0M | 70.9M | -202.3M |
| Operating Cash Flow | -326.4M | 37.2M | 135.0M | 139.8M | -176.2M |
| Investing Activities | |||||
| Capital Expenditures | -3.0M | -1.1M | -3.0M | -8.6M | -1.3M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | 0 | 0 |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -3.0M | -1.1M | -3.0M | -8.6M | -1.3M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | -1.0M | 0 |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 197.1M | 18.5M | -17.3M | 49.7M | -13.1K |
| Free Cash Flow | -183.4M | 7.0M | 7.8M | 4.5M | 18.9M |
| Net Change in Cash | -132.4M | 54.5M | 114.7M | 180.8M | -177.5M |
Cash Flow Trend
Vaishali Pharma Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
133.83
Price to Book
1.57
Price to Sales
0.92
Profitability Ratios
Profit Margin
-0.45%
Operating Margin
5.81%
Return on Equity
1.26%
Return on Assets
0.74%
Financial Health
Current Ratio
2.61
Debt to Equity
23.15
Beta
-0.01
Per Share Data
EPS (TTM)
₹0.06
Book Value per Share
₹5.11
Revenue per Share
₹9.99
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| VAISHALI | 1.0B | 133.83 | 1.57 | 1.26% | -0.45% | 23.15 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.





